KRAS and pancreatic ductal adenocarcinoma: In pancreatic ductal adenocarcinoma (PDAC), co-occurring TP53 and KRAS mutations drive tumor growth and metastasis through interaction with CREB-1 (cAMP responsive element binding protein 1) [55].